Clinical Trial

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Study acronym: Sickle-AID
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-07-10; most recent amendment 2026-04-27.
Trial Details
NCT Number NCT03214354
Lead Sponsor University of Calgary
Conditions Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia
Enrollment 12 participants
Start Date 2017-07-05
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-01